23 February 2018

Contents

Editorial

• 23 February 2018: vol 19 no 4

Conference reports

• CROI 2018 – highlights from the preliminary programme

Antiretrovirals

• FDA grants tentative approval to first DTG/FTC/TAF FDC

Treatment access

• Universal ART on diagnosis: approved by NHS England

Pregnancy

• Standard once-daily dolutegravir dosing achieves target levels during pregnancy

PK and drug interactions

• Significant drug-drug interaction between dolutegravir and isoniazid-rifapentine

Side effects

• Meta-analysis reports no significant risk of cardiac, IRIS or suicide with dolutegravir

Cure-related research

• New data on identifying and targeting the latent HIV reservoir

• Recruiting natural killer cells to target HIV persistence

Other news

• Discrimination against gay men overturned with new HPV vaccine programme for England

• UK study highlights discrimination against trans people living with HIV

On the web

• PrEP resources for access

PDFs

• 23 February 2018: vol 19 no 4